Amgen lipid-lowering drug meets phase three endpoints
Evolocumab, Amgen’s human monoclonal antibody for the treatment of a genetic cause of high cholesterol, has performed well in a phase three trial.
Evolocumab, in combination with statins and other lipid-lowering therapies, met its primary endpoints in the trial in patients with heterozygous familial hypercholesterolemia – giving reductions in low-density lipoprotein cholesterol levels at ten and 12 weeks.
Sean Harper, executive vice-president of R&D, Amgen
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.